Get the Stockscreener App
9.67
6.93%
-0.72
Urogen Pharma Ltd stock is traded at $9.67, with a volume of 741.55K.
It is down -6.93% in the last 24 hours and down -15.55% over the past month.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
See More
Previous Close:
$10.39
Open:
$10.32
24h Volume:
741.55K
Relative Volume:
1.91
Market Cap:
$488.60M
Revenue:
$82.71M
Net Income/Loss:
$-102.24M
P/E Ratio:
-2.6349
EPS:
-3.67
Net Cash Flow:
$-76.57M
1W Performance:
+2.98%
1M Performance:
-15.55%
6M Performance:
-24.69%
1Y Performance:
-32.09%
1-Day Range:
$9.61
$10.60
1-Week Range:
$9.21
$10.83
52-Week Range:
$8.94
$20.70
Urogen Pharma Ltd Stock (URGN) Company Profile
Name
Urogen Pharma Ltd
Sector
Industry
Phone
972 9 770 7601
Address
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
9.67 | 488.60M | 82.71M | -102.24M | -76.57M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-19-25 | Resumed | Ladenburg Thalmann | Buy |
| Aug-22-24 | Initiated | Guggenheim | Buy |
| Feb-08-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-27-22 | Initiated | Berenberg | Buy |
| Apr-16-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-09-20 | Initiated | National Securities | Neutral |
| May-30-19 | Initiated | JP Morgan | Neutral |
| May-29-19 | Initiated | Goldman | Neutral |
| Jan-29-19 | Initiated | H.C. Wainwright | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Apr-04-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-02-18 | Initiated | Ladenburg Thalmann | Buy |
| Nov-15-17 | Reiterated | Oppenheimer | Outperform |
| Nov-15-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
View All
Urogen Pharma Ltd Stock (URGN) Latest News
The Goldman Sachs Group Cuts UroGen Pharma (NASDAQ:URGN) Price Target to $16.00 - Defense World
UroGen Pharma (NASDAQ:URGN) Research Coverage Started at Scotiabank - Defense World
Alliancebernstein L.P. Buys 175,859 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Scotiabank Initiates UroGen Pharma at Sector Outperform With $23 Price Target - marketscreener.com
UroGen Announces Data Presentations at the American Urological A - GuruFocus
UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers - The Joplin Globe
Wellington Management Group LLP Boosts Stake in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
UroGen: June 13 PDUFA For Potential Bladder Cancer Blockbuster Sets Up Strong Buy - Seeking Alpha
KLP Kapitalforvaltning AS Acquires Shares of 5,500 UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
UroGen Pharma stock hits 52-week low at $9.02 - Investing.com Australia
UroGen Pharma Ltd. (NASDAQ:URGN) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
UroGen Pharma stock hits 52-week low at $9.02 By Investing.com - Investing.com Canada
Long Term Trading Analysis for (URGN) - news.stocktradersdaily.com
UroGen Pharma Ltd (URGN) gets rating Resumed from Ladenburg Thalmann - knoxdaily.com
Charles Schwab Investment Management Inc. Boosts Position in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Earnings call transcript: UroGen Pharma Q4 2024 reports mixed results - Investing.com India
Bank of New York Mellon Corp Increases Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Transitional Cell Carcinoma Treatment Market Size in 7MM - openPR
UroGen Pharma Ltd. (NASDAQ:URGN) Receives Average Recommendation of “Buy” from Analysts - Defense World
HC Wainwright Expects Reduced Earnings for UroGen Pharma - Defense World
(URGN) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Urogen pharma outlines $1B revenue potential for UGN-102 with June 2025 launch target - MSN
UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance
UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strat - GuruFocus.com
UroGen Pharma (NASDAQ:URGN) Price Target Cut to $55.00 by Analysts at HC Wainwright - Defense World
UroGen Pharma stock target cut to $55 at H.C. Wainwright By Investing.com - Investing.com Australia
UroGen Pharma stock target cut to $36 at Raymond James By Investing.com - Investing.com Australia
UroGen Pharma stock target cut to $36 at Raymond James - Investing.com India
UroGen Pharma stock target cut to $55 at H.C. Wainwright - Investing.com India
UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2024 Earnings Call Transcript - Insider Monkey
UroGen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral Capital - Defense World
UroGen Pharma Reports Strong Pipeline Progress and Revenue Growth - TipRanks
UroGen Pharma Ltd. SEC 10-K Report - TradingView
Earnings call transcript: UroGen Pharma Q4 2024 reports mixed results By Investing.com - Investing.com South Africa
UroGen Pharma shares fall as Q4 results miss estimates By Investing.com - Investing.com South Africa
UroGen Pharma shares fall as Q4 results miss estimates - Investing.com India
Urogen Pharma Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Urogen Pharma reports wider-than-expected fourth-quarter loss -March 10, 2025 at 10:56 am EDT - Marketscreener.com
Oppenheimer & Co. Inc. Acquires Shares of 11,875 UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
UroGen Pharma earnings missed by $0.03, revenue fell short of estimates - Investing.com Australia
UroGen Pharma Posts Wider Loss In Q4Quick Facts - Nasdaq
UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102 - Joplin Globe
Rhumbline Advisers Has $546,000 Position in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Marketscreener.com
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bluefield Daily Telegraph
UroGen Pharma Ltd. to Host Earnings Call - ACCESS Newswire
UroGen Pharma (URGN) to Release Earnings on Thursday - Defense World
BALVERSA Adoption on the Rise: Meeting Unmet Needs in Advanced Urothelial Cancer | DelveInsight - GlobeNewswire Inc.
How to Take Advantage of moves in (URGN) - Stock Traders Daily
Urogen Pharma Ltd Stock (URGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):